Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RTA 1701 · 1 trial · 1 indication
Safety will be assessed based on the number of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Single Dose of RTA 1701 or Placebo | EXPERIMENTAL | RTA 1701 capsules or placebo taken orally in a single dose. Group 1: RTA 1701 10 mg or matching placebo Group 2: RTA 1701 ≤ 20 mg or matching placebo Group 3: RTA 1701 ≤ 40 mg or matching placebo Group 4: RTA 1701 ≤ 80 mg or matching placebo Group 5: RTA 1701 ≤ 160 mg or matching placebo Group 6: RTA 1701 ≤ 320 mg or matching placebo Group 7: RTA 1701 ≤ 640 mg or matching placebo |
| Multiple Dose of RTA 1701 or Placebo | EXPERIMENTAL | RTA 1701 capsules, Dose TBD mg or placebo taken orally once daily for 14 weeks. Group 8: RTA 1701 ≤40 mg or matching placebo Group 9: RTA 1701 ≤160 mg or matching placebo Group 10: RTA 1701 ≤640 mg or matching placebo |
| Name | Type | Description |
|---|---|---|
| Placebo oral capsule | DRUG | Placebo capsule matched to an RTA 1701 capsule |
| RTA 1701 capsules | DRUG | Capsule containing RTA 1701, multiple dosages |
Inclusion Criteria: * Male or female and age is between 18 and 55 years, inclusive; * Female participants of childbearing potential must: * Not be pregnant, or lactating, or planning a pregnancy, and * Be willing to use contraception (hormonal contraceptives, diaphragm, or intrauterine contraceptio...
RTA 1701 is an investigational small molecule being developed by Biogen Inc. (BIIB). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to evaluate its safety and pharmacokinetic and pharmacodynamic properties.
RTA 1701 is being studied for use in healthy adults. It is an investigational small molecule in Phase 1 development. The completed clinical trial focused on safety and pharmacokinetic and pharmacodynamic parameters in healthy volunteers, not on treating a specific disease.
RTA 1701 is being developed by Biogen Inc., a biotechnology company traded on the NASDAQ under the ticker BIIB. Biogen is the sponsor of the clinical trial for this investigational small molecule.
RTA 1701 is in Phase 1 clinical development. It is an investigational small molecule and is not yet approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing.
RTA 1701 has one completed Phase 1 clinical trial, NCT03579030, titled "Safety and PK/PD of RTA 1701 in Healthy Adults." The trial enrolled 90 healthy participants in Australia, was randomized, double-blind, and controlled, and included adults aged 18 years and older.